Introduction/Study Objectives: Etanercept is a tumor necrosis factor inhibitor indicated for the treatment of several inflammatory disorders. Patients with these diseases may experience manual dexterity challenges. Autoinjectors may improve dose accuracy, treatment adherence, and quality of life, and reduce injection-site reactions. Studies have indicated patients prefer autoinjectors to other injection methods; however, patients must be able to use an autoinjector safely and effectively for it to be a viable option. The YLB113 etanercept autoinjector may be a substitutable biosimilar to reference etanercept (Pfizer Manufacturing; Puurs, Belgium). This study sought to confirm intended users of the YLB113 etanercept autoinjector could use it safely and effectively.
Subscribe now to GaBI Journal to view full information of GaBI Journal published manuscripts.